Horizon Investments LLC Acquires 2,361 Shares of Johnson & Johnson (NYSE:JNJ)

Horizon Investments LLC increased its holdings in Johnson & Johnson (NYSE:JNJ) by 10.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,627 shares of the company’s stock after purchasing an additional 2,361 shares during the quarter. Horizon Investments LLC’s holdings in Johnson & Johnson were worth $3,706,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of JNJ. IFS Advisors LLC boosted its position in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares in the last quarter. Bay Harbor Wealth Management LLC bought a new stake in Johnson & Johnson during the 4th quarter valued at approximately $32,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson during the 3rd quarter valued at approximately $35,000. Activest Wealth Management bought a new stake in Johnson & Johnson during the 3rd quarter valued at approximately $40,000. Finally, NewSquare Capital LLC boosted its position in Johnson & Johnson by 145.8% during the 4th quarter. NewSquare Capital LLC now owns 290 shares of the company’s stock valued at $42,000 after acquiring an additional 172 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of several research reports. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Wells Fargo & Company lowered their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Barclays lifted their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Finally, Citigroup lowered their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $171.33.

Johnson & Johnson Price Performance

Shares of JNJ opened at $164.24 on Wednesday. The firm has a market cap of $395.80 billion, a PE ratio of 24.70, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The firm has a fifty day simple moving average of $155.73 and a two-hundred day simple moving average of $156.25. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.29 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Insider Activity

In other news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.